Discontinuation of First-Line Disease-Modifying Therapy in Patients With Stable Multiple SclerosisEline M. E. Coerver, Eva Strijbis, Jop Mostert et al.|JAMA Neurology|2024Cited by 29
Serum glial fibrillary acidic protein in natalizumab-treated relapsing-remitting multiple sclerosis: An alternative to neurofilament lightMark HJ Wessels, Charlotte E. Teunissen, Bernard M.J. Uitdehaag et al.|Multiple Sclerosis Journal|2023Cited by 17
Aging is associated with reduced inflammatory disease activity independent of disease duration in relapsing multiple sclerosis trial populationsE.M.E. Coerver, Jop Mostert, Bernard M.J. Uitdehaag et al.|Multiple Sclerosis Journal|2024Cited by 13
Exploring the effects of extended interval dosing of natalizumab and drug concentrations on brain atrophy in multiple sclerosisAlyssa A Toorop, Joep Killestein, Eva Strijbis et al.|Multiple Sclerosis Journal|2024Cited by 5
Long-term neuroprotective effects of natalizumab and fingolimod in multiple sclerosis: Evidence from real-world clinical dataSamantha Noteboom, Martijn D. Steenwijk, Bas Jasperse et al.|Multiple Sclerosis and Related Disorders|2024Cited by 5